Pharmafile Logo
Pharmafocus logo
Advanced Search

WHO advises Ukraine to destroy disease-causing pathogens in labs

March 11, 2022
Medical Communications

WHO has advised Ukraine to destroy “disease-causing pathogens” kept in public health labs, to prevent “any potential spills”, Reuters has …

News

NIHR unites with health and social care leaders to improve public research involvement

March 11, 2022
Medical Communications

The National Institute for Health Research (NIHR) has announced a new shared commitment to improve public health in research. The …

News

Domain Therapeutics and Explicyte enter immuno-oncology partnership

March 10, 2022
Business Services

Domain Therapeutics and Explicyte have announced the signing of a partnership agreement. The two companies aim to combine their expertise …

News

AI drug discovery collaboration for rare disease cystinosis

March 10, 2022
Business Services

Insilico Medicine has entered a research and development collaboration with the Mechanisms of Inherited Kidney Disorders (MIKADO) group at the …

News

$31 million to progress pipeline of genetic modifiers in cancer and rare diseases

March 10, 2022
Business Services

Scenic Biotech has announced a Series A financing of roughly $31 million, supporting the creation of new programmes based on …

News

MHRA approves Phase I/II clinical trial of IN3BIO vaccine for colorectal cancer patients

March 10, 2022
Business Services

The MHRA has approved a Phase I/II clinical trial of IN3BIO’s colorectal cancer vaccine. This is the company’s second global …

News

Vicore adds to rare lung disease pipeline with PAH indication

March 9, 2022
Research and Development

Vicore Pharma has announced plans to initiate a clinical trial with C21 in pulmonary arterial hypertension (PAH).

News

NICE draft guidance does not recommend pembrolizumab plus chemo for triple negative breast cancer

March 9, 2022
Research and Development

Draft guidance published by NICE for public consultation does not recommend pembrolizumab in combination with chemotherapy (paclitaxel or nab-paclitaxel) for …

News

Omicron sub-variant BA.2 makes up 11.6% of COVID-19 variants in US

March 9, 2022
Research and Development

The CDC said that the BA.2 sub-variant of Omicron is estimated to be 11.6% of the coronavirus variants circulating in …

News

MHRA authorisation of new treatment for chronic kidney disease associated with diabetes

March 9, 2022
Research and Development

The MHRA has authorised the use of Kerendia® (finerenone) (10mg or 20mg), an oral, first-in-class non-steroidal, selective mineralocorticoid receptor (MR) …

News

Moderna announces its global public health strategy

March 8, 2022

Moderna has announced its global public health strategy through four new initiatives which aim to advance mRNA vaccines for the …

News

Study may see end of need for invasive endometriosis diagnosis surgery

March 8, 2022
Manufacturing and Production

A new study of women living with endometriosis is underway, exploring the potential of Artificial intelligence (AI), and cutting-edge medical …

News

Neuraxpharm expands in Southeast Europe

March 8, 2022
Manufacturing and Production

Neuraxpharm Group have announced the expansion of its business in Southeast Europe, through the acquisition of Brain Therapeutics, a company …

News

Major US study finds COVID-19 vaccines not linked to deaths

March 8, 2022
Manufacturing and Production

A study into vaccine side-effects, based in the US, has found no link between two COVID-19 jabs and the number …

News

Malaysia to receive Pfizer’s COVID-19 pills in two weeks, says Health Minister

March 7, 2022
Sales and Marketing

Khairy Jamaluddin, Health Minister of Malaysia, has shared that the country expects to receive its first shipment of Pfizer’s oral …

News

HUTCHMED receives $15 million to begin Phase III study of lung cancer treatment

March 7, 2022
Sales and Marketing

HUTCHMED has received $15 million from AstraZeneca, for the initiation of start-up activities for SAFFRON, the first global Phase III …

News

AbbVie acquires Syndesi Therapeutics

March 7, 2022
Sales and Marketing

Syndesi Therapeutics has been acquired by AbbVie in a deal worth a potential $1 billion.Syndesi was created in 2018 as …

News

India: approval for drug treating CKD-associated anaemia

March 7, 2022
Sales and Marketing

Zydus Lifesciences received approval from the Drugs Controller General of India (DCGI) for its new drug application for Oxemia (Desidustat). …

News

Phase III trial into nirsevimab for RSV treatment yields positive results

March 4, 2022
Medical Communications

The latest results from Sanofi and AstraZeneca’s Phase III trial nirsevimab support the vaccine’s ability to protect all infants from …

News

Median Technologies iBiopsy Lung Cancer Screening Software

March 4, 2022
Medical Communications

Median Technologies has announced that the company has filed a regulatory submission to the FDA for its iBiopsy Lung Cancer …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025